Home > Insider Trading > Filing (0000911916-15-000186)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348649	Colucid Pharmaceuticals Inc.	CLCD	Pharmaceutical Preparations (2834)	203419541

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1639971	Luc Marengere	15 New England Executive Park Burlington MA 01803		Yes	No	Yes	No
1640880	L.p. Vii Ventures Science Life Tvm	204, Rue Notre-Dame Ouest, Bureau 350 Montreal A8 H2Y 1T3		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-05-11	995,386	$0.00	995,386	No	4	C	Indirect	By TVM Life Science Ventures VII L.P.
Common Stock	Acquisiton	2015-05-11	500,000	$10.00	1,495,386	No	4	P	Indirect	By TVM Life Science Ventures VII L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By TVM Life Science Ventures VII L.P.
No	4	P	Indirect	By TVM Life Science Ventures VII L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Convertible Preferred Stock	Disposition	2015-05-11	995,386	$0.00	995,386	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Each share of Series C Convertible Preferred Stock was convertible at any time at the option of the holder, and converted automatically into shares of the Issuer's Common Stock on a one-for-one basis in connection with the closing of the Issuer's initial public offering.
Represents securities held directly by TVM Life Science Ventures VII L.P. TVM Life Science Ventures VII (GP) Ltd. is the general partner of TVM Life Science Ventures VII L.P. The reporting person is a managing partner of the investment team of TVM Life Science Venture Capital, which has voting and investment power with respect to these shares. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The securities did not have an expiration date. The securities converted automatically into shares of the Issuer's Common Stock on a one-for-one basis in connection with the closing of the Issuer's initial public offering.